Related Experiment Video

Updated: Jul 22, 2025

Author Spotlight: Exploring Mitochondrial Function and Chemical Toxicity Using Drosophila melanogaster
09:20

Author Spotlight: Exploring Mitochondrial Function and Chemical Toxicity Using Drosophila melanogaster

Published on: November 10, 2023

1000

Improving mitochondrial function in preclinical models of heart failure: therapeutic targets for future clinical

Anna Gorący1, Jakub Rosik2, Joanna Szostak3

  • 1Department of Clinical and Molecular Biochemistry, Pomeranian Medical University, Szczecin, Poland.

Expert Opinion on Therapeutic Targets
|July 21, 2023
PubMed
Abstract

Insights

Mitochondrial dysfunction contributes to heart failure. New therapeutic strategies targeting mitochondria and reducing oxidative stress show promise for improving heart function and slowing disease progression.

Area of Science:

  • Cardiology
  • Mitochondrial Biology
  • Pharmacology

Background:

  • Heart failure arises from myocardial damage and compensatory metabolic pathway disruptions.
  • Mitochondrial dysfunction exacerbates cardiomyocyte dysfunction in heart failure.
  • Current therapies for mitochondrial dysfunction in heart failure have variable efficacy.

Purpose of the Study:

  • To review novel therapeutic strategies targeting mitochondrial function for heart failure treatment.
  • To explore new research models for restoring mitochondrial metabolic processes.
  • To identify promising combined strategies for heart failure management.

Main Methods:

  • Literature review of current and emerging therapeutic approaches.
  • Analysis of research models for mitochondrial dysfunction in heart failure.
  • Evaluation of combined therapeutic strategies.

Main Results:

  • Targeting mitochondria offers a potential therapeutic avenue for heart failure.
  • Developing comprehensive models to restore mitochondrial metabolism is crucial.
  • Combined strategies reducing oxidative stress and mitochondrial dysfunction are promising.

Conclusions:

  • New therapeutic models are needed to address disrupted mitochondrial processes in heart failure.
  • Comprehensive treatment targeting multiple dysregulated mitochondrial processes is key for clinical improvement.
  • Combined therapies hold significant potential for managing heart failure progression.
Keywords:
Mitochondriaheartheart failuretargetstherapeutic strategies

More Related Videos

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer11:26

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer

Published on: February 13, 2019

8.8K
Author Spotlight: Uncovering the Role of Mitochondrial Calcium Phosphate in Heart Failure and Bioenergetics07:03

Author Spotlight: Uncovering the Role of Mitochondrial Calcium Phosphate in Heart Failure and Bioenergetics

Published on: August 23, 2024

868

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
14.5K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
14
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
17
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
465
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
628